前沿速览038期| CAR-T治B淋 前沿览新知
01
大B细胞淋巴瘤患者CAR-T细胞制备失败的风险因素及其患者结局：英国国家CAR-T小组报告
Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel
第一作者：Dulobdas V
Blood Cancer J (IF=12.9). 2025 Mar 4;15(1):30.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11876324/
02
整合互补激活信号的定制化CAR可增强NK细胞的抗肿瘤活性
A chimeric antigen receptor tailored to integrate complementary activation signals potentiates the antitumor activity of NK cells
第一作者：Yi E
J Exp Clin Cancer Res (IF=11.4). 2025 Mar 6;44(1):86.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11884141/
03
Lisocabtagene maraleucel vs. mosunetuzumab用于治疗≥三线复发/难治性滤泡性淋巴瘤的疗效与安全性：一项匹配校正间接比较
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma
第一作者：Nastoupil LJ
Exp Hematol Oncol (IF=9.4). 2025 Mar 5;14(1):30.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11881270/
04
Lisocabtagene maraleucel vs. axicabtagene ciloleucel治疗大B细胞淋巴瘤的真实世界数据比较：一项3年随访的治疗逆概率加权分析
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up
第一作者：Portuguese AJ
Haematologica (IF=8.2). 2025 Mar 13.
全文网址：https://haematologica.org/article/view/11977
05
自体干细胞移植联合CAR-T细胞治疗复发/难治性B细胞淋巴瘤：一项单臂临床研究
Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical study
第一作者：Li D
Front Immunol (IF=5.7). 2025 Feb 26;16:1532460.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11897563/
06
清淋前淋巴细胞/单核细胞与乳酸脱氢酶比值对接受CAR-T细胞治疗的弥漫大B细胞淋巴瘤患者结局的影响
Lymphocyte/monocyte to lactate dehydrogenase ratio prior to lymphodepletion impact the outcomes of patients with diffused large B cell lymphoma undergoing CAR-T cell therapy
第一作者：Li N
Cancer Immunol Immunother (IF=4.6). 2025 Mar 15;74(5):148. doi: 10.1007/s00262-025-03987-4.
全文网址：https://link.springer.com/article/10.1007/s00262-025-03987-4
07
CAR-T细胞疗法在八旬B细胞淋巴瘤老年患者中的应用：一项美国多中心真实世界协作研究
Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study
第一作者：Kharfan-Dabaja MA
Bone Marrow Transplant (IF=4.5). 2025 Mar 1.
全文网址：https://www.nature.com/articles/s41409-025-02541-1
08
大B细胞淋巴瘤患者的肿瘤基因表达特征与接受axicabtagene ciloleucel治疗的结局相关
Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel)
第一作者：Tian Y
Front Oncol (IF=3.5). 2025 Feb 27;15:1519473.
全文网址：https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1519473/full
09
关于优化tisagenlecleucel在日本患者中的商业化生产：一项4年的经验之旅
Optimizing the commercial manufacturing of tisagenlecleucel for patients in Japan: A 4-year experiential journey
第一作者：Iwamoto F
Regen Ther (IF=3.4). 2025 Feb 21;28:619-624.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11891598/
10
单细胞和Bulk转录组学的综合分析可识别调节性T细胞特征，其可作为弥漫大B细胞淋巴瘤预后的预测因子
Comprehensive Analysis of Single-Cell and Bulk Transcriptomics Identified Regulatory T-Cell Features as Predictors of Prognosis in Diffuse Large B-Cell Lymphoma
第一作者：Cui Y
Hematol Oncol (IF=3.3). 2025 Mar;43(2):e70050.
全文网址：https://onlinelibrary.wiley.com/doi/epdf/10.1002/hon.70050
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2025.3-17 valid until 2027.3
供稿与审核：临床开发与医学部